Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

Initiating treatment with a reduced dose of enzalutamide did not significantly decrease the incidence rate of AEs, and it showed poorer PSA response rate. There is no clear rationale for treating with a reduced initial dose of enzalutamide to reduce the incidence of AEs.